Dynamic plasma proteome signatures predict response and survival in advanced AG/GEJC under PD-1 inhibitor plus chemotherapy
Abstract
Immune checkpoint inhibitors (ICIs) plus chemotherapy are standard first-line therapy for advanced gastric (GC) and gastroesophageal junction cancer (GEJC), yet predictive biomarkers remain limited. In this prospective single-center study, 31 patients with advanced GC/GEJC receiving PD-1 inhibitor plus chemotherapy were enrolled. Plasma samples were collected at baseline and every two cycles. Immune-related proteins were quantified using the Olink Target 96 Immuno-Oncology panel.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Gastric Cancer Management and Outcomes
Inflammatory Biomarkers in Disease Prognosis
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 16 January 2026
- Document type
- Dataset